Thyroid Hormones for Depression? This Tiny Trial Just Made Big Pharma Pay Attention.
Autobahn Therapeutics just dropped Phase 2 data for a brain-targeted thyroid drug in bipolar depression, and the numbers are raising eyebrows. A tiny trial, no placebo arm, and yet the signal might be too strong to ignore.
Doctors have been sneaking thyroid hormones into depression treatment for decades. It's one of psychiatry's worst-kept secrets: add a little T3 to an antidepressant, and some patients who weren't getting better suddenly start improving. The problem? Flooding the whole body with thyroid hormone is like turning the thermostat up to 90 because one room is cold. Your heart races, your bones thin, and your endocrinologist starts leaving concerned voicemails.
Autobahn Therapeutics thinks it cracked the code. The San Diego biotech just reported Phase 2 results for elunetirom (ABX-002), a pill designed to deliver thyroid hormone activity only to the brain. And in a small trial of patients with bipolar depression, the results were striking enough to send the company racing toward a pivotal Phase 3 study.
A Drug That Knows Where to Go
Elunetirom is what's called a thyroid hormone receptor beta (TRβ) agonist, which means it mimics the effects of thyroid hormone on a specific receptor concentrated in the brain. But the clever part isn't the target; it's the delivery system.
Autobahn built elunetirom as a prodrug (think of it as a locked pill that only unlocks inside the brain). It exploits an enzyme called FAAH that's heavily concentrated in brain tissue. When the drug reaches the brain, FAAH activates it. Meanwhile, a companion molecule blocks that same enzyme everywhere else in the body. The result: high drug levels where you want them, low levels where you don't.
It's like a VIP pass that only works at one club.
Once active in the brain, elunetirom is designed to boost cellular energy production, stimulate the growth of new neural connections, and strengthen the synaptic wiring that depression disrupts. The company believes this creates a fundamentally different kind of antidepressant effect, one rooted in restoring brain metabolism rather than simply adjusting serotonin or dopamine levels.
The Numbers That Got People Talking
The trial, called AMPLIFY-BD, enrolled 21 adults with bipolar I or II depression. All patients kept taking their existing mood stabilizers while adding once-daily elunetirom for six weeks. It was open-label (no placebo group), which is important to note. But the magnitude of improvement turned heads anyway.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Patients scored their depression on the HAMD-17, a standard 17-item questionnaire used in virtually every depression trial. At Week 6, the average score dropped by 16.8 points (p < 0.001). For context, a 3-point change on this scale is often considered clinically meaningful. This was nearly six times that.
The speed was notable, too. By Week 2, patients had already improved by 9.7 points. Three-quarters of patients hit the bar for "response" (a 50% or greater reduction in symptoms), and half achieved full remission by the end of six weeks.
Brain Scans Backed It Up
Autobahn didn't just measure symptoms; they looked inside patients' brains. Using functional neuroimaging, the trial tracked changes in how different brain regions communicate with each other (a measure called resting-state functional connectivity). By Week 6, researchers saw statistically significant improvements in connectivity across regions that are highly relevant to depression.
This is the kind of biomarker data that regulators and investors both love. It suggests the drug isn't just making people feel better through some nonspecific effect. It appears to be changing the underlying neural circuitry.
On safety, the results were equally clean. All treatment-related side effects were mild to moderate. No serious or severe treatment-related adverse events were reported, and there was no signal of the manic switch that psychiatrists always worry about with bipolar patients.
The Elephant in the Room: 21 Patients, No Placebo
Let's be honest about the limitations. Twenty-one patients is tiny. And without a placebo arm, it's impossible to know exactly how much of the improvement came from the drug versus the natural course of the illness, regression to the mean, or the powerful effects of being in a clinical trial (the so-called placebo response, which is notoriously high in depression studies).
Autobahn's leadership clearly knows this. The company has stated it plans to engage with the FDA to map out a registration path, and elunetirom already holds Fast Track designation for adjunctive bipolar depression. A randomized, placebo-controlled Phase 3 trial is the obvious next step, and based on public statements, the company appears to be moving quickly toward one.
Why Bipolar Depression Is Such a Hard Nut to Crack
Bipolar depression is a notoriously difficult indication. Patients spend far more time depressed than manic, yet the approved treatment options are limited to a handful of atypical antipsychotics (quetiapine, lurasidone, cariprazine, lumateperone) and the combination of olanzapine plus fluoxetine. Many of these come with significant metabolic side effects, sedation, or movement problems that limit adherence.
The pipeline isn't exactly overflowing either. NRX-101, a combination of D-cycloserine and lurasidone, is the furthest along in Phase 3 but targets a narrow niche: bipolar depression with active suicidality. Ketamine-based approaches address acute crises but require IV infusion and close monitoring. A biomarker-guided neuroplasticity agent from Alto Neuroscience (ALTO-100) is in Phase 2b. Beyond that, pickings are slim.
Elunetirom occupies a different lane entirely. It's an oral, once-daily pill aimed at broad adjunctive use in outpatient settings, with a mechanism that no competitor shares. If the Phase 3 data hold up, it could fill a genuine gap.
The Money and the Momentum
Autobahn isn't some two-person garage startup. The company raised a $100 million Series C in July 2024, led by Newpath Partners, with a syndicate that reads like a who's-who of biotech venture capital: ARCH Venture Partners, Canaan Partners, Insight Partners, BVF Partners, Samsara BioCapital, and Section 32. Three major pharma companies (Biogen, Bristol Myers Squibb, and Pfizer Ventures) also participated as strategic investors.
That kind of investor list doesn't guarantee success, but it signals that serious people have done serious diligence.
The company has another catalyst on deck: a separate Phase 2 trial of elunetirom in major depressive disorder (MDD) is expected to deliver topline results in the third quarter of 2026. If both bipolar and MDD data look strong, Autobahn suddenly has a dual-indication story that could make it one of the most attractive private biotechs in the CNS space.
The Bottom Line
Twenty-one patients in an open-label trial won't win anyone an approval. But the signal here is hard to ignore: a 16.8-point HAMD drop, 75% response, 50% remission, clean safety, and brain imaging that corroborates the clinical picture. All from a first-in-class mechanism that nobody else is developing for mood disorders.
The real test comes next. Phase 3 will need to prove this holds up against placebo in a much larger group of patients. Bipolar depression has humbled plenty of promising drugs before. But if elunetirom can thread that needle, Autobahn may have found something psychiatry has been chasing for a very long time: the brain benefits of thyroid hormones, without the body paying the price.
5 min read
Rallybio Just Gave Away 97% of Itself (and Investors Are Thrilled)
Rallybio is handing 97% of its company to a private oncology startup, and some of biotech's biggest investors just piled $215 million into the deal. Here's why a reverse merger with Avenzo Therapeutics might be the most interesting deal structure in biotech this year.
